Summary

Optical Genome Mapping Market Growth & Trends

The global optical genome mapping market size is estimated to reach USD 656.2 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 29.1% from 2023 to 2030. This can be attributed to developments in studying efficient treatments for a variety of chronic diseases. The ability of optical genome mapping (OGM) to complement other genomic sequencing technologies, such as next-generation sequencing (NGS), has created synergies in genomics research.

Researchers can integrate optical mapping data with NGS data to obtain a more comprehensive view of the genome, which is particularly valuable in clinical diagnostics and cancer research. In August 2023, Bionano Genomics participated in the Cancer Genomics Consortium (CGC) 2023 annual meeting with a wide range of sessions covering the utility of OGM for hematological malignancy and solid tumor cancer research, including poster presentations and scientific platform from Bionano Genomics, which also featured a panel discussion of esteemed researchers from across the cancer genomics field.

Technological advancements have played a significant role in the growth of the OGM industry. Over the years, there have been substantial improvements in the underlying technologies used in optical mapping. High-resolution imaging techniques, such as fluorescence microscopy, have become more sophisticated, enabling researchers to visualize and analyze individual DNA molecules with unprecedented precision. Advancements in DNA labeling methods and data analysis algorithms have enhanced the accuracy and efficiency of OGM, making it a reliable and robust tool for genomic research. In June 2023, Bionano Genomics introduced the Stratys system for high throughput OGM via software for evaluating genomic data for hematologic malignancies.

Moreover, the accessibility of optical mapping technology has also improved, making it more widely available to researchers and institutions. Several companies have developed commercial optical mapping platforms, offering turnkey solutions for genomics research. This commercialization has not only made optical mapping more accessible but has also accelerated its adoption across different sectors.

Optical Genome Mapping Market Report Highlights

• Based on product, the market is segmented into instruments, consumables and reagents, software, services, and others. The services segment dominated the market with a revenue share of 39.1% in 2022. This is attributed to the technological advancements in instruments and the increasing number of service providers. The consumables and reagents segment is expected to grow at a lucrative CAGR over the forecast period

• Based on application, the structural variant detection segment dominated the market in 2022 with a revenue share of 49.2%. In contrast, the genome assembly segment is anticipated to exhibit the second fastest CAGR over the forecast period owing to the expanding research on gene expressions, genomic diversity, and complex data sequencing

• Based on end-users, the academic research institutes segment dominated the market in 2022 with a revenue share of 59.1%. On the other hand, the hospitals and clinical laboratories segment is expected to grow at a lucrative CAGR of 25.0% owing to the increasing investment in new drug targets and therapeutic approaches

• Based on region, North America dominated the market in 2022 with the largest revenue share of 43.4%, owing to the growing investments and funding in the biotechnology sector

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Information Analysis
1.2.2. Market Formulation & Data Visualization
1.2.3. Data Validation & Publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Advancements in genomic research
3.2.1.2. Rising government funding and research initiatives
3.2.2. Market Restraint Analysis
3.2.2.1. Cost of equipment and consumables
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Optical Genome Mapping Market: Product Movement Analysis
4.2. Instruments
4.2.1. Instruments Market, 2018 - 2030 (USD Million)
4.3. Consumables and Reagents
4.3.1. Consumables and Reagents Market, 2018 - 2030 (USD Million)
4.4. Software
4.4.1. Software Market, 2018 - 2030 (USD Million)
4.5. Services
4.5.1. Services Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Optical Genome Mapping Market: Application Movement Analysis
5.2. Structural Variant Detection
5.2.1. Structural Variant Detection Market, 2018 - 2030 (USD Million)
5.3. Genome Assembly
5.3.1. Genome Assembly Market, 2018 - 2030 (USD Million)
5.4. Microbial Strain Typing
5.4.1. Microbial Strain Typing Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. End-user Business Analysis
6.1. Optical Genome Mapping Market: End-user Movement Analysis
6.2. Biotechnology and Pharmaceutical Companies
6.2.1. Biotechnology and Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
6.3. Clinical Laboratories
6.3.1. Clinical Laboratories Market, 2018 - 2030 (USD Million)
6.4. Academic research institutes
6.4.1. Academic research institutes Market, 2018 - 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Optical Genome Mapping Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.4.6. Singapore
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Singapore Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.5. Rest of the World
7.5.1. Rest of the World Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Mexico Optical Genome Mapping Market, 2018 - 2030 (USD Million)
7.5.4. South Africa
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. South Africa Optical Genome Mapping Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2022
8.4. Company Profiles
8.4.1. Bionano Genomics
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Nucleome Informatics Private Limited
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Praxis Genomics, LLC
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. SourceBio International Limited (Source BioScience)
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. MedGenome
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. INRAE (French Plant Genomic Resources Center (CNRGV))
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. PerkinElmer (PerkinElmer Genomics)
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Genohub Inc.
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Hofkens Lab
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Cerba
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives